Website: https://impala-consortium.org/The Inter coMPany quALity Analytics (IMPALA) Consortium’s mission is to transform the Biopharmaceutical Clinical Quality Assurance process in the Good Clinical Practice and Good Pharmacovigilance Practice areas, by using advanced analytics and promoting the adoption of this new approach and associated methodologies by key industry stakeholders (e.g. pharma quality professionals, Health Authorities) to assure safe use, therefore building patient trust, accelerating approvals and ultimately benefiting patients globally. The IMPALA Consortium will provide the strategic focus for working across the Biopharmaceutical ecosystem to develop and gain industry-wide consensus for the adoption of improved QA using advanced analytics and best practices to be used across the industry.
Program News
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium (Media Coverage)
Date: 02 Apr 2024
Clinical Trial Anomaly Spotter (CTAS) Package Now Available (Media Coverage)
Date: January 22, 2024
RQA features a session from IMPALA Consortium titled “Overview of IMPALA Industry Group and its impact on modernizing GCP/PV Quality.” (Press Release)
Date: 01 Apr 2023
IMPALA welcomes new members in an article written by ISTO. (Press Release)
Date: 01 Apr 2023
IMPALA Consortium Welcome New Members (Press Release)
Date: 26 May 2023
RQA Quality Conversation Session (Press Release)
Date: 10 May 2023
IEEE Spectrum Feature: Big Data Could Accelerate Drug Approvals (Press Release)
Date: 15 Feb 2023
RQA Workshop on Data Analytics Write-Up Now Available (Press Release)
Date: 29 Nov 2022
Clinical Safety Reporting Work Product Stream (Press Release)
Date: 15 Nov 2022
Official Launch of Inter Company Quality Analytics (IMPALA) Consortium (Press Release)
Date: 03 Nov 2022